How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,082 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Air Travel and Pregnancy

–security–scanner]. Scientific Impact Paper 1 © Royal College of Obstetricians and Gynaecologists 5of 67. Centers for Disease Control and Prevention. Travelling While Pregnant. [http://wwwnc.cdc.gov/ travel/yellowbook/2012/chapter–8–advising–travelers–with–specific–needs/pregnant–travelers.htm]. 8. Hezelgrave NL, Whitty CJ, Shennan AH, Chappell LC. Advising on travel during pregnancy. BMJ 2011;342:d2506. 9. Civil Aviation Authority. Guidance for Health Professionals Information on assessing fitness (...) Air Travel and Pregnancy Air Travel and Pregnancy Scientific Impact Paper No. 1 May 2013Air Travel and Pregnancy This is the third edition of this paper, which was published in 2001 and 2005 under the title ‘Advice on Preventing Deep Vein Thrombosis (DVT) for Pregnant Women Travelling by Air’. 1. Background Obstetricians are commonly asked to give advice on whether it is suitable for women who are pregnant to fly during pregnancy. Such advice is sought because of the physiological

2013 Royal College of Obstetricians and Gynaecologists

102. A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. (Abstract)

A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women. Pregnancy-related venous thromboembolism (VTE) is one of the leading causes of maternal morbidity and mortality.To review the epidemiology, and humanistic and economic burden of pregnancy-related VTE.Medline, the Cochrane Central Register of Controlled Trials, Econlit, Science Direct, JSTOR, Oxford Journals, and Cambridge Journals were searched for reports published between (...) January 2000 and December 2012. Keywords related to VTE, pregnancy, and epidemiology and the humanistic and economic burdens were combined.Eligible studies evaluated the incidence, mortality, recurrence, complications, quality-of-life, and economic burden of VTE among pregnant women, and had been published in English.Background information of the study, participants' characteristics, and study outcomes were collected. Meta-analyses of data were performed.Twenty studies were included, none of which

2015 International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

103. ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism

= Peptic Ulcer Disease ,TIA= Transient ischemic attack, USA= Unstable angina, Vitamin K antagonist=Warfarin, VKA=Vitamin K antagonist, VTE=Venous Thromboembolism, Yr=Year DISCLAIMER: The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of Saskatoon Health Region (SHR). Neither the authors nor Saskatoon Health Region nor any other party who has been involved in the preparation or publication of this work warrants (...) ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 ASPIRE: Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism 1 Aspirin to Prevent Recurrent Venous Thromboembolism BOTTOM LINE • In patients whom have had an unprovoked VTE with low to moderate bleed risk the addition of ASA 100 mg daily is reasonable to prevent future VTE events and major vascular events if the decision is made

2013 RxFiles

104. Management of Acute Atrial Fibrillation and Atrial Flutter in Non-Pregnant Hospitalized Adults

A2 Age =75 years 2 D Diabetes Mellitus 1 S2 Prior Stroke or TIA or thromboembolism 2 V Vascular disease (e.g. peripheral artery disease, myocardial infarction, aortic plaque) 1 A Age 65–74 years 1 Sc Sex category (i.e. female gender) 1 Table 3: When to consider a rhythm control strategy for atrial fibrillation/flutter • First occurrence of symptomatic AF/AFL • Occurrence or recurrence of AF due to reversible cause (e.g. hyperthyroidism, pulmonary embolism, postoperative state, pneumonia, acute (...) • Consideration of an accessory pathway • Consideration of rhythm control • Control of heart rate • Anticoagulation Often, several of these categories of treatment will be applied, in parallel. However, the main goals of AF/AFL with RVR management are symptomatic improvement (via rate/or rhythm control), and prevention of thromboembolic complications (with antiplatelet or anticoagulant medications). An overview of the management of stable AF/AFL is illustrated in Figure 2. Treatment of underlying conditions

2017 University of Michigan Health System

105. A single-center experience with 12 consecutive cases of pregnancy among patients with membranous ventricular septal aneurysm. Full Text available with Trip Pro

A single-center experience with 12 consecutive cases of pregnancy among patients with membranous ventricular septal aneurysm. Membranous ventricular septal aneurysm (MVSA) is a rare cardiac anomaly that can occur as an isolated entity or being associated with other cardiac malformations. Complications of MVSA include thromboembolism, arrhythmia, rupture, bacterial endocarditis, right ventricular outflow tract obstruction, and atrioventricular valve diseases.The success rate of pregnancy (...) and delivery in patients with MVSA has not been reported in the literature. This study was to assess the clinical implications of this condition from our center's experience.This was a retrospective study for consecutive 12 pregnancies in women with MVSA, who delivered at a tertiary care center in west China between May 2008 and March 2015.All patients with MVSA delivered via caesarian section. One patient with severe pulmonary arterial hypertension expired from pulmonary infection and heart failure after

2018 BMC Pregnancy and Childbirth

106. ACOG Practice Bulletin No. 197 Summary: Inherited Thrombophilias in Pregnancy. (Abstract)

ACOG Practice Bulletin No. 197 Summary: Inherited Thrombophilias in Pregnancy. Inherited thrombophilias are associated with an increased risk of venous thromboembolism and have been linked to adverse outcomes in pregnancy. However, there is limited evidence to guide screening for and management of these conditions in pregnancy. The purpose of this document is to review common thrombophilias and their association with maternal venous thromboembolism risk and adverse pregnancy outcomes (...) , indications for screening to detect these conditions, and management options in pregnancy. This Practice Bulletin has been revised to provide additional information on recommendations for candidates for thrombophilia evaluation, updated consensus guidelines regarding the need for prophylaxis in women with an inherited thrombophilia during pregnancy and the postpartum period, and discussion of new published consensus guidelines from the Society for Obstetric Anesthesia and Perinatology addressing

2018 Obstetrics and Gynecology

107. ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. (Abstract)

ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Inherited thrombophilias are associated with an increased risk of venous thromboembolism and have been linked to adverse outcomes in pregnancy. However, there is limited evidence to guide screening for and management of these conditions in pregnancy. The purpose of this document is to review common thrombophilias and their association with maternal venous thromboembolism risk and adverse pregnancy outcomes, indications (...) for screening to detect these conditions, and management options in pregnancy. This Practice Bulletin has been revised to provide additional information on recommendations for candidates for thrombophilia evaluation, updated consensus guidelines regarding the need for prophylaxis in women with an inherited thrombophilia during pregnancy and the postpartum period, and discussion of new published consensus guidelines from the Society for Obstetric Anesthesia and Perinatology addressing thromboprophylaxis

2018 Obstetrics and Gynecology

108. Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

airway pressure (CPAP) in pregnancy will result in a reduction in the rate of hypertensive disorders of pregnancy. Condition or disease Intervention/treatment Phase Obstructive Sleep Apnea of Adult Preeclampsia Obstetrical Complications Device: Continuous Positive Airway Pressure Other: Sleep Hygiene Control Not Applicable Detailed Description: Emerging data support a link between sleep disordered breathing (SDB) and adverse pregnancy outcomes. In particular, women with obstructive sleep apnea (OSA (...) by The George Washington University Biostatistics Center: CPAP Apnea pregnancy Additional relevant MeSH terms: Layout table for MeSH terms Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Pre-Eclampsia Obstetric Labor Complications Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Hypertension, Pregnancy-Induced Pregnancy Complications

2018 Clinical Trials

109. Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia

reactions of rhTPO in the treatment of pregnancy-induced thrombocytopenia. Condition or disease Intervention/treatment Phase Immune Thrombocytopenia Drug: recombinant human thrombopoietin Drug: Platelet Concentrate Phase 3 Detailed Description: The project is undertaken by Qilu Hospital of Shandong University and other 6 well-known hospitals in China. The investigators anticipate to undertaking a concurrent control, multicentre trial including 60 pregnancy associated ITP adult patients which (...) of the serum urea nitrogen, creatinine, serum transaminase and bilirubin ); No severe cardiac and pulmonary dysfunction; No history of mental illness; Voluntarily signed written informed consent. Exclusion Criteria: A history of serious allergies to biologics; The history of thrombosis; Thromboembolic or hemorrhagic disease; Patients who are deemed unsuitable for the study by the investigator. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2018 Clinical Trials

110. Tranexamic Acid in Pregnancies With Vaginal Bleeding

Description Go to Brief Summary: Tranexamic acid has been proposed and used for prevention and management of antepartum and postpartum hemorrhage. Condition or disease Intervention/treatment Phase Vaginal Bleeding During Pregnancy Drug: Tranexamic Acid Not Applicable Detailed Description: Bleeding during pregnancy is associated with a three- to fourfold increase in perinatal mortality. Hemorrhage in pregnancy is characterized by activation of the fibrinolytic system. Tranexamic acid is a potent (...) pharmaceutical agent that suppresses fibrinolysis, and thus can be used for managing hemorrhage in pregnancy. The FDA's pregnancy category for tranexamic acid is Category B. It crosses the placenta however; its lack of effect on plasminogen activator activity in the vascular cell wall protects the fetus and newborn from potential thromboembolic complications. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 79 participants Intervention

2018 Clinical Trials

111. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

or myocardial infarction. 19,20 DVT is associated with an increased risk for PE and postphlebitic syndrome, a condition characterized by chronic pain, swelling, and ulceration. 21 Untreated PE is associated with a hospital mortality 9 Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program rate of 5.4 to 15 percent. 22,23 Furthermore, the cumulative incidence of chronic thromboembolic pulmonary hypertension 2 years after the diagnosis (...) Thromboembolic diseases represent a major public health burden and are associated with significant morbidity and mortality. For over 50 years, vitamin K antagonists (VKAs) have been the mainstay of treatment and prophylaxis of thromboembolism. There are many indications for VKA, including primary prevention of systemic embolism in nonvalvular atrial fibrillation (AF) and mechanical prosthetic heart valves. Other indications include secondary prophylaxis following venous thromboembolism (VTE) and preventing

2012 Veterans Affairs Evidence-based Synthesis Program Reports

112. Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. (Abstract)

Pregnancy outcome in patients with sickle cell disease in the UK--a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. We describe the findings from a national study of maternal and fetal outcomes of pregnancy in women with sickle cell disease (SCD). Data were collected via the United Kingdom Obstetric Surveillance System between 1 February 2010 and 31 January 2011 from 109 women, of whom 51 (46·8%) had HbSS and 44 (40·4%) had HbSC. Data included antenatal, maternal (...) and fetal outcomes. Comparisons were made between women with HbSS and HbSC. Incidence of complications were acute pain (57%), blood transfusion (26%), urinary tract infection (UTI; 12%) and critical care unit admission (23%) and these were all more common in women with HbSS than HbSC. There was no difference in the incidence of acute chest syndrome, hypertension and venous thromboembolism between HbSS and HbSC. Women with HbSS were more likely to deliver at <37 weeks gestation (P = 0·01

2015 British journal of haematology

113. Pregnancy and venous thromboembolism. (Abstract)

Pregnancy and venous thromboembolism. This review provides a concise and complete overview of diagnostic work-up and treatment of venous thromboembolism in pregnancy, with attention to recent research developments and recent applicable guidelines. This may be useful for all the players of the multidisciplinary interaction needed in this disease management, namely cardiologists and gynecological/obstetric teams.Venous thromboembolism is, in the developed world, a major cause of maternal (...) and watchful eyes, deciding on a case-to-case and actively contributing in reducing pregnancy-related morbidity.Although there is an ongoing debate on various aspects of this condition and there is a paucity of high-quality studies, this review attempts to simplify the complex aspects of joining safety and efficacy in diagnosing and treating a possible two-people life-threatening disease.

2014 Current Opinion in Obstetrics and Gynecology

114. Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. Full Text available with Trip Pro

Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. The antiphospholipid syndrome (APS) is defined by simultaneous presence of vascular clinical events and antiphospholipid antibodies (aPL). The aPL considered as diagnostics are lupus anticoagulant and antibodies anticardiolipin (aCL) and anti-ß2 glycoprotein-I (aB2GP1). During recent years, IgA aB2GP1 antibodies have been associated with thrombotic events both in patients positive, and mainly (...) negative for other aPL, however its value as a pro-thrombotic risk-factor in asymptomatic patients has not been well defined.To test the role of IgA anti B2GP1 as a risk factor for the development of APS-events (thrombosis or pregnancy morbidity) in asymptomatic population with a 5-year follow-up.244 patients isolated positive for anti-beta2-glycoprotein I IgA (Group-1 study) and 221 negative patients (Group-2 control) were studied. All the patients were negative for IgG and IgM aCL.During the follow

2017 PLoS ONE

115. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Full Text available with Trip Pro

Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a preventable cause of in-hospital death, and one of the most prevalent vascular diseases. There is a lack of knowledge with regards to contemporary presentation, management and outcomes of patients with VTE. Many clinically important subgroups (including the elderly, those with recent (...) bleeding and pregnant patients) have been under-represented in clinical trials. Furthermore, design of clinical trials is challenging in some scenarios, such as in those with hemodynamically unstable PE. RIETE (Registro Informatizado Enfermedad TromboEmbolica) is a large prospective multinational ongoing registry, designed to address these unmet needs using representative data from multiple centres. Initiated in Spain in 2001, RIETE currently includes 179 centres in 24 countries and has enrolled more

2018 Thrombosis and haemostasis

116. Postpartum venous thromboembolism prophylaxis: harm versus benefit. Full Text available with Trip Pro

. 2018 Aug;125(9):1195-1196 30004639 Female Humans Postpartum Period Pregnancy Pregnancy Complications, Cardiovascular Puerperal Disorders Venous Thromboembolism Venous Thrombosis 2018 2 24 6 0 2019 2 27 6 0 2018 2 24 6 0 ppublish 29473281 10.1111/1471-0528.15182 (...) Postpartum venous thromboembolism prophylaxis: harm versus benefit. 29473281 2019 02 26 2019 02 26 1471-0528 125 9 2018 08 BJOG : an international journal of obstetrics and gynaecology BJOG Postpartum venous thromboembolism prophylaxis: harm versus benefit. 1117 10.1111/1471-0528.15182 Arya R R Department of Haematological Medicine, King's College Hospital, London, UK. eng Journal Article Comment 2018 04 15 England BJOG 100935741 1470-0328 AIM IM BJOG. 2018 Aug;125(9):1109-1116 29512316 BJOG

2018 BJOG

117. Galectin-3 for Thromboembolic Formation in Patients With Atrial Fibrillation CHAâ‚‚DSâ‚‚-VASc Scoring

to presence or absence of another clinical risk factors. Condition or disease Atrial Fibrillation Stroke Detailed Description: In 2001, the CHADS₂ score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke) was developed to predict the risk of stroke in patients with non rheumatic atrial fibrillation.In this score, each patient giving one point for congestive heart failure , hypertension , age equal or more than 75 years, diabetes mellitus and two points for stroke, transient (...) years. Diagnosed as non valvular atrial fibrillation patients either paroxysmal or persistent types. Exclusion Criteria: pregnancy valvular heart diseases. Congenital heart diseases. Heart failure. Ischemic heart disease. Inflammatory diseases. Cancer. Thyroid disease. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2018 Clinical Trials

118. Anticoagulant therapies for acute venous thromboembolism: a comparison between those discharged directly from the emergency department versus hospital in two Canadian cities. Full Text available with Trip Pro

Anticoagulant therapies for acute venous thromboembolism: a comparison between those discharged directly from the emergency department versus hospital in two Canadian cities. To compare the characteristics/management of acute venous thromboembolism (VTE) for patients either discharged directly from the emergency department (ED) or hospitalised throughout a year within two urban cities in Canada.Retrospective medical record review.Hospitals in Edmonton, Alberta (n=4) and Regina, Saskatchewan (n (...) =2) from April 2014 to March 2015.All patients discharged from the ED or hospital with acute deep vein thrombosis or pulmonary embolism (PE). Those having another indication for anticoagulant therapy, pregnant/breast feeding or anticipated lifespan <3 months were excluded.Primarily, to compare proportion of patients receiving traditional therapy (parenteral anticoagulant±warfarin) relative to a direct oral anticoagulant (DOAC) between the two cohorts. Secondarily, to assess differences

2018 BMJ open

119. Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic

thromboembolism in cirrhotic, so the investigators will do a study to demonstrate frequency and risk factors for acute venous thromboembolism in cirrhotic patients, find a conventional laboratory method and test TEG to assess risk of thrombosis in cirrhotic patients.Also, to validate current algorithm for use of anticoagulant and antiplatelet for thromboembolism for non cirrhotic in cirrhotic patients. Condition or disease Intervention/treatment Liver Cirrhosis Venous Thromboembolism Device (...) ) Exclusion Criteria: Patient with chronic thromboembolic event ( e.g. chronic pulmonary embolism, chronic portal vein thrombosis). patients on antiplatelets or anticoagulants. Patients with end stage kidney, heart or lung diseases Pregnant. Cirrhotic patients on control group who develop an acute thromboembolic event during the study period will be excluded and shifted to the case group Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2018 Clinical Trials

120. PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)

Update Posted : February 19, 2019 See Sponsor: Sunnybrook Health Sciences Centre Collaborators: Sunnybrook Research Institute Canadian Institutes of Health Research (CIHR) Information provided by (Responsible Party): Sunnybrook Health Sciences Centre Study Details Study Description Go to Brief Summary: This is a pilot study, phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI). Condition or disease Intervention/treatment Phase Traumatic (...) -regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: No Keywords provided by Sunnybrook Health Sciences Centre: Sequential Compression Device Anticoagulant Thromboprophylaxis Deep Vein Thrombosis Sub Cutaneous VTE Additional relevant MeSH terms: Layout table for MeSH terms Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Thromboembolism Venous Thromboembolism Brain Diseases Central Nervous System Diseases Nervous

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>